{"id":"montelukast-mon","safety":{"commonSideEffects":[{"rate":"18-20%","effect":"Headache"},{"rate":"3-4%","effect":"Abdominal pain"},{"rate":"2-3%","effect":"Diarrhea"},{"rate":"2-3%","effect":"Dyspepsia"},{"rate":"rare but FDA-warned","effect":"Neuropsychiatric effects (mood changes, suicidality)"}]},"_chembl":null,"_dailymed":{"setId":"1a312a28-8472-4cab-a7dd-d01cd8b2765a","title":"MONTELUKAST SODIUM (MONTELUKAST SODIUM) TABLET, CHEWABLE [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leukotrienes are inflammatory mediators released by mast cells and eosinophils that bind to CysLT1 receptors, triggering airway smooth muscle contraction, mucus secretion, and eosinophil recruitment. By antagonizing these receptors, montelukast reduces the inflammatory cascade underlying asthma and allergic rhinitis, decreasing airway hyperresponsiveness and symptoms.","oneSentence":"Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:49.775Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (maintenance and acute prevention)"},{"name":"Allergic rhinitis"},{"name":"Exercise-induced bronchoconstriction"}]},"trialDetails":[{"nctId":"NCT00296491","phase":"PHASE4","title":"Study Of Allergic Rhinitis In Patients Who Also Have Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Asthma","enrollment":725}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"montelukast (MON)","genericName":"montelukast (MON)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction. Used for Asthma (maintenance and acute prevention), Allergic rhinitis, Exercise-induced bronchoconstriction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}